A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
Malignant Pleural Mesothelioma
DRUG: Nivolumab|DRUG: Pemetrexed|DRUG: Cisplatin or Carboplatin
number of patients going to operating room for surgical resection, Patients who experience a greater than 30 day toxicity induced delay of surgery will be counted as a failure for the primary feasibility endpoint., 30 days of the initially planned date
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.